Dalton Receives Notice of Award from NIDA of NIH to Fund Research
News Sep 06, 2013
Dalton Medicinal Chemistry has received notice of award from the National Institute On Drug Abuse (NIDA) to research and discover a novel series of compounds with the potential to treat drug abuse and alleviate pain.
This work will be supported by NIDA of the National Institutes of Health (NIH) under Award Number R21DA036251 which includes funding for the project.
Dalton Medicinal Chemistry will utilize their proprietary knowledge and expertise to design, synthesize and test several novel classes of compounds for these applications.
Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: “It is exceptionally exciting to receive notice of this competitive award from National Institute On Drug Abuse (NIDA) which germinated from the creative insights of the talented scientists at Dalton. We are delighted to have the opportunity to initiate and conduct this important research.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Researchers Develop Novel ‘One-pot’ Approach to Conjugated Tetraenes SynthesisNews
TUAT researchers have achieved the new synthetic route of conjugated tetraenes from inexpensive and easily available 1,3-butadiene and substituted acetylenes by a one-pot approach under mild conditions. Conjugated tetraenes are important key substructures in biologically active natural products such as vitamins, and anti-mycotic drugs.READ MORE